Proactive Investors - Run By Investors For Investors

Sareum surges as its flagship Chk1 inhibitor continues to produce encouraging data

Researchers in Texas found that SRA737, when combined with immunotherapy and low dose gemcitabine, had a “dramatic enhancement” in anti-tumour activity
scientist in lab
SRA737 has been licensed by Sierra Oncology, which is taking it through the clinic

Sareum Holdings PLC (LON:SAR) surged on Thursday morning as its SRA737 checkpoint kinase 1 (Chk1) inhibitor continues to impress.

Chk1 controls a cancer cell's response to DNA damage, which could be caused by the disease itself or intentionally caused by chemotherapy or radiotherapy.

READ: Sareum primed for progress

Sierra Oncology Inc (NASDAQ:SRRA), the US firm which has licensed SRA737, has published pre-clinical data showing it had a “dramatic enhancement” in anti-tumour activity when combined with immunotherapy and low dose gemcitabine – one of the most commonly prescribed chemotherapies.

“These new studies reveal a striking immunomodulatory effect of SRA737 + LDG that results in some of the most profound synergistic activity with anti-PD-L1 therapy that we have observed in this model,” said Lauren Byers, associate professor at the University of Texas MD Anderson cancer center.

“We are excited by the potential clinical translatability of these findings and their possible broader impact on immune checkpoint blockade strategies.”

Research house Hybridan added: “This three-way combination is another potential addition to SRA737’s development programme which stands to generate significant further milestones and in due course royalties for Sareum.”

The data is being presented at the American Association of Cancer Research annual meeting in Atlanta, Georgia next month.

In afternoon trading in London, Sareum shares were 12.5% higher 0.68p.

Reporting results today, Sierra CEO Nick Glover commented: "We have enrolled a substantial number of patients into the two ongoing trials for our oral Chk1 inhibitor, SRA737, and remain on track to report clinical data from these studies in the first half of 2019."

In pre-market trading in New York, Sierra Oncology shares were 11.5% higher at $2.0299.

 -- Adds Sierra comment, share price --

View full SAR profile View Profile

Sareum Holdings PLC Timeline

Big Picture
February 22 2019

Related Articles

scientist in a lab
April 12 2019
Danish giant Novo Nordisk recently signed up to use its NDD platform, and bosses expect more collaboration deals in the coming months
cannabis
February 27 2019
The company is a leader for dried flower vaporizers, and a pioneer in cannabis telemedicine and AI technologies
Cameron Durrant
March 04 2019
A goal is to improve the safety of CAR-T therapies, used in the treatment of children with acute lymphoblastic leukemia and adults with advanced lymphomas

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use